Your browser doesn't support javascript.
loading
Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).
Mikolajczyk, Rafael; Diexer, Sophie; Klee, Bianca; Pfrommer, Laura; Purschke, Oliver; Fricke, Julia; Ahnert, Peter; Gabrysch, Sabine; Gottschick, Cornelia; Bohn, Barbara; Brenner, Hermann; Buck, Christoph; Castell, Stefanie; Gastell, Sylvia; Greiser, Karin Halina; Harth, Volker; Heise, Jana-Kristin; Holleczek, Bernd; Kaaks, Rudolf; Keil, Thomas; Krist, Lilian; Leitzmann, Michael; Lieb, Wolfgang; Meinke-Franze, Claudia; Michels, Karin B; Velásquez, Ilais Moreno; Obi, Nadia; Panreck, Leo; Peters, Annette; Pischon, Tobias; Schikowski, Tamara; Schmidt, Börge; Standl, Marie; Stang, Andreas; Völzke, Henry; Weber, Andrea; Zeeb, Hajo; Karch, André.
Afiliação
  • Mikolajczyk R; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. Electronic address: rafael.mikolajczyk@uk-halle.de.
  • Diexer S; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Klee B; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Pfrommer L; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Purschke O; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Fricke J; Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Ahnert P; Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig, Germany.
  • Gabrysch S; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Public Health, Berlin, Germany; Research Department 2, Potsdam Institute for Climate Impact Research (PIK), Member of the Leibniz Association, Potsdam, Germany; Heidelb
  • Gottschick C; Institute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Bohn B; NAKO e.V., Heidelberg, Germany.
  • Brenner H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Buck C; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
  • Castell S; Department for Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  • Gastell S; NAKO Study Centre, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
  • Greiser KH; Division of Cancer Epidemiology, DKFZ Heidelberg, Heidelberg, Germany.
  • Harth V; Institute for Occupational and Maritime Medicine Hamburg (ZfAM), University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • Heise JK; Department for Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  • Holleczek B; Krebsregister Saarland, Saarbrücken, Germany.
  • Kaaks R; Division of Cancer Epidemiology, DKFZ Heidelberg, Heidelberg, Germany.
  • Keil T; Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany; Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany; State Institute of Health I, Bavarian Health and Food Safety Authority, Erlangen, German
  • Krist L; Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Leitzmann M; Institute of Epidemiology and Preventive Medicine, Regensburg, Germany.
  • Lieb W; Institute of Epidemiology, Kiel University, Kiel, Germany.
  • Meinke-Franze C; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
  • Michels KB; Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical Centre, University of Freiburg, Freiburg, Germany.
  • Velásquez IM; Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Molecular Epidemiology Research Group, Berlin, Germany.
  • Obi N; Institute for Occupational and Maritime Medicine Hamburg (ZfAM), University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • Panreck L; NAKO e.V., Heidelberg, Germany.
  • Peters A; Institute of Epidemiology, Helmholtz Zentrum München - German Research Centre for Environmental Health (GmbH), Neuherberg, Germany; Chair of Epidemiology, Institute for Medical Information Processing, Biometry and Epidemiology, Medical Faculty, Ludwig-Maximilians-Universität München, Munich, Germany
  • Pischon T; Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Molecular Epidemiology Research Group, Berlin, Germany.
  • Schikowski T; IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany.
  • Schmidt B; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
  • Standl M; Institute of Epidemiology, Helmholtz Zentrum München - German Research Centre for Environmental Health (GmbH), Neuherberg, Germany; German Centre for Lung Research (DZL), Munich, Germany.
  • Stang A; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
  • Völzke H; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
  • Weber A; Institute of Epidemiology and Preventive Medicine, Regensburg, Germany.
  • Zeeb H; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany; Health Sciences Bremen, University of Bremen, Bremen, Germany.
  • Karch A; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
J Infect ; 89(2): 106206, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38897239
ABSTRACT

OBJECTIVES:

The risk of Post-COVID-19 condition (PCC) under hybrid immunity remains unclear.

METHODS:

Using data from the German National Cohort (NAKO Gesundheitsstudie), we investigated risk factors for self-reported post-infection symptoms (any PCC is defined as having at least one symptom, and high symptom burden PCC as having nine or more symptoms).

RESULTS:

Sixty percent of 109,707 participants reported at least one previous SARS-CoV-2 infection; 35% reported having had any symptoms 4-12 months after infection; among them 23% reported nine or more symptoms. Individuals, who did not develop PCC after their first infection, had a strongly reduced risk for PCC after their second infection (50%) and a temporary risk reduction, which waned over 9 months after the preceding infection. The risk of developing PCC strongly depended on the virus variant. Within variants, there was no effect of the number of preceding vaccinations, apart from a strong protection by the fourth vaccination compared to three vaccinations for the Omicron variant (odds ratio = 0.52; 95% confidence interval 0.45-0.61).

CONCLUSIONS:

Previous infections without PCC and a fourth vaccination were associated with a lower risk of PCC after a new infection, indicating diminished risk under hybrid immunity. The two components of risk reduction after a preceding infection suggest different immunological mechanisms.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article